Cambridge-based Owlstone Medical has received £1.7m from the Cystic Fibrosis Foundation to develop a breath test for pseudomonas aeruginosa (PA) detection in patients with cystic fibrosis. PA is a germ that can cause infections in the blood, lungs, or other parts of the body after surgery. The MedTech, which is a global leader in breath … Continue reading MedTech giant raises funding to target severe medical threat